Delly PHR - Atossa Therapeutics VP HR
| YAG2 Stock | EUR 1.15 0.04 3.60% |
Insider
Delly PHR is VP HR of Atossa Therapeutics
| Phone | 206 588 0256 |
| Web | https://www.atossatherapeutics.com |
Atossa Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.113) % which means that it has lost $0.113 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1833) %, meaning that it generated substantial loss on money invested by shareholders. Atossa Therapeutics' management efficiency ratios could be used to measure how well Atossa Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| John Eldh | ScanSource | 55 | |
| Gregory Dixon | ScanSource | N/A | |
| James Koch | The Boston Beer | 73 | |
| Mary Gentry | ScanSource | N/A | |
| John Geist | The Boston Beer | 63 | |
| Jason Weidman | ScanSource | N/A | |
| Carolyn OBoyle | The Boston Beer | 44 | |
| Tara Heath | The Boston Beer | 48 | |
| Matthew Murphy | The Boston Beer | 54 | |
| Lesya Lysyj | The Boston Beer | 60 | |
| Mark Morgan | ScanSource | N/A | |
| Paul Weaver | The Boston Beer | N/A | |
| Michael Baur | ScanSource | 66 | |
| Rachel Hayden | ScanSource | N/A | |
| Frank Smalla | The Boston Beer | 57 | |
| Alexandre Conde | ScanSource | N/A | |
| Frank Blackwell | ScanSource | N/A | |
| Stephen Jones | ScanSource | 51 | |
| David Burwick | The Boston Beer | 61 | |
| Samuel III | The Boston Beer | 53 | |
Management Performance
| Return On Equity | -0.18 | |||
| Return On Asset | -0.11 |
Atossa Therapeutics Leadership Team
Elected by the shareholders, the Atossa Therapeutics' board of directors comprises two types of representatives: Atossa Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Atossa. The board's role is to monitor Atossa Therapeutics' management team and ensure that shareholders' interests are well served. Atossa Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Atossa Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Heather Rees, VP Accounting | ||
| FCAP MD, CEO Chairman | ||
| Delly PHR, VP HR | ||
| RAC MSPH, Quality Regulatory | ||
| Richard MD, Interim Officer | ||
| CPA Esq, Gen CFO |
Atossa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Atossa Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | |||
| Return On Asset | -0.11 | |||
| Current Valuation | (59.13 M) | |||
| Shares Outstanding | 126.62 M | |||
| Shares Owned By Insiders | 0.04 % | |||
| Shares Owned By Institutions | 20.65 % | |||
| Price To Book | 0.64 X | |||
| EBITDA | (20.5 M) | |||
| Net Income | (20.61 M) | |||
| Cash And Equivalents | 131.49 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Atossa Stock
Atossa Therapeutics financial ratios help investors to determine whether Atossa Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Atossa with respect to the benefits of owning Atossa Therapeutics security.